Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Vor Biopharma (NASDAQ:VOR) and maintained a price target of $11. The reaffirmation of the rating and price target suggests confidence in the company's prospects.
January 18, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reaffirmed an Outperform rating on Vor Biopharma with a price target of $11, indicating a positive outlook on the company's stock.
The reiteration of an Outperform rating and the maintenance of a price target by a reputable analyst like David Nierengarten can be seen as a strong positive endorsement of Vor Biopharma's stock. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100